Critical IllnessMPV-CICUNCT07656311
Mean Platelet Volume (MPV) as an Early Predictor of Mortality in Intensive Care Patients With Cancer
An observational study of Critical Illness and Cancer, run by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
This study aims to investigate whether Mean Platelet Volume (MPV) and other blood count parameters measured at admission can predict mortality in cancer patients admitted to the intensive care unit (ICU). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Critical Illness, Cancer, Mortality
- How many people
- 425 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 Jun 2026to 1 Aug 2026
- How long will I take part?
- 30 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of adult oncological patients who required critical care and were admitted to the anesthesia intensive care unit of a tertiary oncology training and research hospital between 2020 and 2025.
Who may be able to join
- Adult patients aged 18 years and older.
- Patients with a pathologically or clinically confirmed diagnosis of cancer (solid or hematological malignancies).
- Patients who were admitted to the Anesthesia Intensive Care Unit (ICU) between 2020 and 2025.
- Patients with an ICU length of stay longer than 24 hours.
- Patients with complete medical records, including baseline complete blood count (CBC) and Mean Platelet Volume (MPV) measured at the time of ICU admission.
Who cannot join
- Patients under the age of 18.
- Patients who stayed in the intensive care unit for less than 24 hours.
- Patients with missing or incomplete medical charts, laboratory data, or survival status records.
- Patients who were readmitted to the ICU during the same hospital stay (only the first admission will be evaluated).
- Patients who received massive blood or platelet transfusions immediately prior to the baseline laboratory measurement, which could artificially alter platelet parameters.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
Ankara
About this study
This study aims to investigate whether Mean Platelet Volume (MPV) and other blood count parameters measured at admission can predict mortality in cancer patients admitted to the intensive care unit (ICU). Patients with cancer are highly vulnerable to complications and organ failure, making early risk assessment vital for improving treatment strategies. Researchers will retrospectively review the medical charts and electronic health records of adult patients who stayed in the anesthesia ICU for longer than 24 hours between 2020 and 2025. No new laboratory tests, interventions, or patient contact will occur. The collected data will be analyzed to determine the relationship between initial MPV levels and patient survival outcomes.
Read the detailed description
This retrospective, observational, single-center study will evaluate the predictive value of initial Mean Platelet Volume (MPV) and other hemogram parameters (such as Red Cell Distribution Width [RDW] and platelet count) on intensive care and hospital mortality. The primary objective is to investigate the correlation between these routinely measured, cost-effective biomarkers and survival outcomes in oncological critical care patients. The study hypotheses are structured as follows:
- H0: There is no significant relationship between the admission MPV value and intensive care or hospital mortality in intensive care patients with cancer.
- H1: There is a significant relationship between the admission MPV value and intensive care or hospital mortality in intensive care patients with cancer. Data regarding demographics (age, sex), clinical diagnoses, comorbidities, length of stay, APACHE II, SOFA scores, and laboratory parameters (CRP, procalcitonin) will be extracted from hospital electronic database records. All patient data will be anonymized before statistical analysis.
Note on Study Design: This study is designed as a retrospective cohort study. Due to system registry constraints in the protocol module, the time perspective has been specified as 'Other' (Retrospective Cohort).
- Conditions
- Critical Illness, Cancer, Mortality
- Keywords
- Mean Platelet Volume, cancer, Intensive Care Unit, ICU Mortality, Biomarkers, MPV
- Medical subject headings
- Critical Illness, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Oncological ICU Patients | Adult patients (aged 18 and older) with a confirmed cancer diagnosis who were admitted to the anesthesia intensive care unit for longer than 24 hours between the years 2020 and 2025 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Intensive Care Unit (ICU) Mortality
The percentage of oncological patients who died during their stay in the anesthesia intensive care unit. This will be calculated based on the electronic health records and patient files.
Measured: From the date of ICU admission up to ICU discharge, assessed up to 30 days.
Secondary outcomes (1)
Hospital Mortality
The percentage of oncological patients who died during their overall hospital stay (including post-ICU ward follow-up).
Measured: From the date of hospital admission up to hospital discharge, assessed up to 60 days.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jun 2026
- Study start15 Jun 2026
- Primary completion1 Aug 2026
- Study completion1 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Critical IllnessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 425 participants (actual)
- Target duration
- 30 Days
Sponsor and investigators
- Lead sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Eda Cennet Caferoğlu, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07656311
- Sponsor's protocol ID
- 2026-05/106
- Acronym
- MPV-CICU
- Status last verified
- Jun 2026
- First submitted
- 15 Jun 2026
- Last updated
- 2 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared globally to maintain patient confidentiality and privacy in accordance with local data protection regulations and institutional review board restrictions. However, the coded datasets and statistical analyses used during the current study may be available from the corresponding author upon reasonable academic request.
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mean Platelet Volume (MPV) as an Early Predictor of Mortality in Intensive Care Patients With Cancer
- ClinicalTrials.gov ID
- NCT07656311
- Acronym / sponsor ID
- MPV-CICU / 2026-05/106
- Conditions
- Critical Illness, Cancer, Mortality
- Keywords
- Mean Platelet Volume, cancer, Intensive Care Unit, ICU Mortality, Biomarkers, MPV
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 425 participants (actual)
- Lead sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalUniversity, hospital or other
- Study start
- 15 Jun 2026 (actual)
- Primary completion
- 1 Aug 2026 (actual)
- Study completion
- 1 Aug 2026 (actual)
- First posted
- 18 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to investigate whether Mean Platelet Volume (MPV) and other blood count parameters measured at admission can predict mortality in cancer patients admitted to the intensive care unit (ICU). Patients with cancer are highly vulnerable to complications and organ failure, making early risk assessment vital for improving treatment strategies. Researchers will retrospectively review the medical charts and electronic health records of adult patients who stayed in the anesthesia ICU for longer than 24 hours between 2020 and 2025. No new laboratory tests, interventions, or patient contact will occur. The collected data will be analyzed to determine the relationship between initial MPV levels and patient survival outcomes.
Detailed description
This retrospective, observational, single-center study will evaluate the predictive value of initial Mean Platelet Volume (MPV) and other hemogram parameters (such as Red Cell Distribution Width [RDW] and platelet count) on intensive care and hospital mortality. The primary objective is to investigate the correlation between these routinely measured, cost-effective biomarkers and survival outcomes in oncological critical care patients. The study hypotheses are structured as follows:
- H0: There is no significant relationship between the admission MPV value and intensive care or hospital mortality in intensive care patients with cancer.
- H1: There is a significant relationship between the admission MPV value and intensive care or hospital mortality in intensive care patients with cancer. Data regarding demographics (age, sex), clinical diagnoses, comorbidities, length of stay, APACHE II, SOFA scores, and laboratory parameters (CRP, procalcitonin) will be extracted from hospital electronic database records. All patient data will be anonymized before statistical analysis.
Note on Study Design: This study is designed as a retrospective cohort study. Due to system registry constraints in the protocol module, the time perspective has been specified as 'Other' (Retrospective Cohort).
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 30 Days
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Oncological ICU Patients | – | –Adult patients (aged 18 and older) with a confirmed cancer diagnosis who were admitted to the anesthesia intensive care unit for longer than 24 hours between the years 2020 and 2025 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of adult oncological patients who required critical care and were admitted to the anesthesia intensive care unit of a tertiary oncology training and research hospital between 2020 and 2025.
Key inclusion criteria (5 listed)
- Adult patients aged 18 years and older.
- Patients with a pathologically or clinically confirmed diagnosis of cancer (solid or hematological malignancies).
- Patients who were admitted to the Anesthesia Intensive Care Unit (ICU) between 2020 and 2025.
- Patients with an ICU length of stay longer than 24 hours.
- Patients with complete medical records, including baseline complete blood count (CBC) and Mean Platelet Volume (MPV) measured at the time of ICU admission.
Key exclusion criteria (5 listed)
- Patients under the age of 18.
- Patients who stayed in the intensive care unit for less than 24 hours.
- Patients with missing or incomplete medical charts, laboratory data, or survival status records.
- Patients who were readmitted to the ICU during the same hospital stay (only the first admission will be evaluated).
- Patients who received massive blood or platelet transfusions immediately prior to the baseline laboratory measurement, which could artificially alter platelet parameters.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Intensive Care Unit (ICU) Mortality
Time frame: From the date of ICU admission up to ICU discharge, assessed up to 30 days.
The percentage of oncological patients who died during their stay in the anesthesia intensive care unit. This will be calculated based on the electronic health records and patient files.
1 secondary outcome
Hospital Mortality
Time frame: From the date of hospital admission up to hospital discharge, assessed up to 60 days.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared globally to maintain patient confidentiality and privacy in accordance with local data protection regulations and institutional review board restrictions. However, the coded datasets and statistical analyses used during the current study may be available from the corresponding author upon reasonable academic request.
Related trials for Critical Illness
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Recruiting
Development and Preliminary Validation of Intelligent Video Laryngoscope for Emergency Use
Critically Ill Patients Requiring Mechanical Ventilation
Active, not recruiting
Weighted Blankets for Agitation in Adults in the Intensive Care Unit
Psychomotor Agitation, Critical Illness
Not yet recruitingObservational study
Core Competencies in General Intensive Care Ultrasound (GenIUS): a Delphi Study
Critical Illness, Ultrasound
RecruitingObservational study
Predicting Extubation Failure Using Machine Learning
Extubation Failure, Critical Illness
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Critical Illness and Cancer, run by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intensive Care Unit (ICU) Mortality (time frame: From the date of ICU admission up to ICU discharge, assessed up to 30 days.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.